Research programme: Nanobodies - Ablynx

Drug Profile

Research programme: Nanobodies - Ablynx

Alternative Names: ABX-0401; ABX-0402; ABX-0403; ALX-0962 (anti-IgE antibody); Anti-IgE Nanobody; Anti-TNF Nanobodies; Anti-VWF Nanobody

Latest Information Update: 13 Sep 2015

Price : $50

At a glance

  • Originator Ablynx
  • Class Proteins
  • Mechanism of Action IgE receptor antagonists; Immunomodulators; Interleukin 6 receptor modulators; RANK ligand inhibitors; Von Willebrand factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombotic thrombocytopenic purpura
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Allergic asthma; Autoimmune disorders; Bone disorders; Inflammation; Respiratory syncytial virus infections; Thrombotic thrombocytopenic purpura
  • Research Cancer; Infections; Respiratory tract disorders

Most Recent Events

  • 07 May 2013 Preclinical development of ALX 0962 for severe Allergic asthma initiated in Belgium
  • 07 May 2013 Ablynx plans a phase I trial of ALX 0962 for severe Allergic asthma in second half of 2014
  • 01 Mar 2012 Preclinical trials in Asthma in Belgium (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top